Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder

Phase 3

Completed

• Conditions: Sexual Dysfunctions, Psychological
• Interventions: Drug: flibanserin flexible dose

• Registration Number: NCT00601367
• Lead Sponsor: Sprout Pharmaceuticals, Inc

Brief Summary

Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2008-01-15
• Study First Submitted QC: 2008-01-25
• Study First Posted: 2008-01-28
• Primary Completion: 2009-10
• Study Completion: 2009-10
• Results First Submitted: 2014-04-22
• Status Verified: 2014-05
• Results First Submitted QC: 2014-05-20
• Last Update Submitted: 2014-05-20
• Results First Posted: 2014-06-20
• Last Update Posted: 2014-06-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 480

Inclusion Criteria

• Women with a primary diagnosis of HSDD who still needs to be treated according to the investigator's opinion and willing to continue in this study. This continuation requires adequate compliance, in the Investigators judgement, with trial medication and the trial visit required in the parent clinical trial (Visit 1 to visit 9).
• Patients must have used a medically acceptable method of contraception [i.e., double barrier method (e.g., diaphragm or condom and spermicide), hormonal therapy (subcutaneous, injectable, intra-vaginal, or oral contraceptive), intrauterine device, tubal sterilization, or partner's surgical sterilization] for at least 3 months before the Screen Visit and continue to use that medically acceptable method of contraception during the trial.

Exclusion Criteria

• Patients with a history of MDD within 6 months prior the Screen Visit or a score of 14 on the Beck Depression Inventory II, or a history of suicide attempt according to the Beck Scale for Suicide Ideation, or patient with any non-zero statement in the first five items for the Beck Scale for Suicide Ideation.
• Patients must have a clinically acceptable Pap smear as read by a cytology facility (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before the Inclusion Visit.
• Patients with findings at the Screen Visit of pelvic inflammatory disease, urinary tract or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia, or significant vaginal atrophy.
• Patients experiencing major life stress (including parenting pressure, eldercare, loss of income, death of a family member, etc.) or relationship discord that could interfere with sexual activity, except distress about HSDD.
• Clinically significant ECG abnormalities at the Screen Visit, according to the investigators opinion or the cardiologist who have performed the ECG. The following ECG values are considered to be exclusionary: QTc intervals >480 milliseconds (ms), PR intervals >240 ms, and QRS intervals >110 ms.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
flibanserin flexible dose	flibanserin flexible dose	Initial dosage: Patients were to take one 50 mg flibanserin tablet in the evening. Subsequent dosage titrations: Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient. Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY. Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site.

Primary Outcome Measures

Name	Time	Method
Frequency of Adverse Events	28 weeks

Trial Locations

Locations (68)

511.118.43005 Boehringer Ingelheim Investigational Site; 🇦🇹 Innsbruck, Austria

511.118.43002 Boehringer Ingelheim Investigational Site; 🇦🇹 Wien, Austria

511.118.43004 Boehringer Ingelheim Investigational Site; 🇦🇹 Wien, Austria

511.118.43006 Boehringer Ingelheim Investigational Site; 🇦🇹 Wörgl, Austria

511.118.32004 Boehringer Ingelheim Investigational Site; 🇧🇪 Braine-l'Alleud, Belgium

511.118.32003 Boehringer Ingelheim Investigational Site; 🇧🇪 Edegem, Belgium

511.118.32005 Boehringer Ingelheim Investigational Site; 🇧🇪 Gent, Belgium

511.118.32006 Boehringer Ingelheim Investigational Site; 🇧🇪 Hasselt, Belgium

511.118.32002 Boehringer Ingelheim Investigational Site; 🇧🇪 Yvoir, Belgium

511.118.42001 Boehringer Ingelheim Investigational Site; 🇨🇿 Olomouc, Czech Republic

Scroll for more (58 remaining)